journal article·2018-09-14

Antitumor activity and antitumor mechanism of triphenylphosphonium chitosan against liver carcinoma

Haochao Huang, Haiwei Wu, Yongrui Huang, Shuangying Zhang, Yuetwai Lam, Ningjian Ao

Journal of Materials Research· Volume 33· Issue 17
Publisher page

Abstract

N-(3-Carboxypropyl) triphenylphosphonium bromide chitosan (TPPB-CS) was synthesized and characterized by FTIR,1H NMR spectrometer, and Zeta potential. TPPB-CS showed a selectivity-toxicity among cancer cell lines (MG-63 and HepG2 cells) and mouse embryonic fibroblast cells (NIH3T3 cells). A significant effect on inhibiting cell migration in HepG2 cells was observed in vitro, and TPPB-CS could effectively inhibit tumor growth in H22-bearing mice in vivo. Furthermore, the distribution of cell cycle, the level of reactive oxygen species (ROS), mitochondrial transmembrane potential (Δψm), the expression of tumor necrosis factor α (TNF-α), and vascular endothelial growth factor (VEGF) were examined to investigate the antitumor mechanism of TPPB-CS. The results suggested that the antitumor activity of TPPB-CS may be attributed to delay the cell cycle in S phase, alter the ROS and Δψmlevel, as well as regulate the TNF-α and VEGF secretion. TPPB-CS can become a promising anticancer drug for clinical therapy.
Source: expertdata · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Synthesis and biological activity · Multicomponent Synthesis of Heterocycles · Synthesis and Characterization of Heterocyclic Compounds

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (50)

Show source-provided references
1. 10.1016/j.addr.2008.04.01610.1016/j.addr.2008.04.016 ↗
2. 10.1038/nature0720510.1038/nature07205 ↗
3. 10.1016/S0009-2509(03)00234-310.1016/S0009-2509(03)00234-3 ↗
4. 10.1021/acsami.5b0040510.1021/acsami.5b00405 ↗
5. 10.1016/j.cbi.2009.05.00610.1016/j.cbi.2009.05.006 ↗
6. 10.1016/j.carbpol.2013.05.03610.1016/j.carbpol.2013.05.036 ↗
7. 10.1006/gyno.1996.002610.1006/gyno.1996.0026 ↗
8. 10.1016/j.ijbiomac.2010.12.00610.1016/j.ijbiomac.2010.12.006 ↗
9. 10.1007/s11095-011-0566-710.1007/s11095-011-0566-7 ↗
10. 10.1039/C4RA07467J10.1039/C4RA07467J ↗
11. 10.1016/j.biomaterials.2013.01.07810.1016/j.biomaterials.2013.01.078 ↗
12. 10.1159/00001189710.1159/000011897 ↗
13. 10.1016/j.progpolymsci.2006.06.00110.1016/j.progpolymsci.2006.06.001 ↗
14. 10.1016/j.cbi.2009.12.00810.1016/j.cbi.2009.12.008 ↗
15. 10.1007/s00280-003-0726-510.1007/s00280-003-0726-5 ↗
16. 10.1016/j.ijbiomac.2014.08.03310.1016/j.ijbiomac.2014.08.033 ↗
17. 10.1021/bm060336m10.1021/bm060336m ↗
18. 10.1093/jn/134.4.94510.1093/jn/134.4.945 ↗
19. 10.1016/j.carbpol.2010.03.00910.1016/j.carbpol.2010.03.009 ↗
20. 10.1016/S0092-8674(04)00166-710.1016/S0092-8674(04)00166-7 ↗
21. 10.1016/j.addr.2009.09.00410.1016/j.addr.2009.09.004 ↗
22. 10.3322/caac.2133210.3322/caac.21332 ↗
23. 10.1039/c3tb20884b10.1039/c3tb20884b ↗
24. 10.1016/j.carbpol.2015.02.03910.1016/j.carbpol.2015.02.039 ↗
25. 10.1016/j.jconrel.2007.11.01810.1016/j.jconrel.2007.11.018 ↗
26. 10.1038/nature0762310.1038/nature07623 ↗
27. 10.1016/j.colsurfb.2011.02.02910.1016/j.colsurfb.2011.02.029 ↗
28. 10.1016/j.freeradbiomed.2011.02.03210.1016/j.freeradbiomed.2011.02.032 ↗
29. 10.1002/cncr.2659510.1002/cncr.26595 ↗
30. 10.1021/acs.molpharmaceut.5b0032010.1021/acs.molpharmaceut.5b00320 ↗
31. 10.1016/j.critrevonc.2010.08.00110.1016/j.critrevonc.2010.08.001 ↗
32. 10.1016/j.drup.2004.01.00410.1016/j.drup.2004.01.004 ↗
33. 10.1016/j.cbi.2011.07.00410.1016/j.cbi.2011.07.004 ↗
34. 10.1081/LPR-6495810.1081/LPR-64958 ↗
35. 10.1016/j.carbpol.2015.04.04010.1016/j.carbpol.2015.04.040 ↗
36. 10.1385/IR:23:2-3:26310.1385/IR:23:2-3:263 ↗
37. 10.1016/j.biomaterials.2012.03.03210.1016/j.biomaterials.2012.03.032 ↗
38. 10.1016/j.addr.2008.09.00110.1016/j.addr.2008.09.001 ↗
39. Phosphonium salts exhibiting selective anti-carcinoma activity in vitro
40. 10.1016/j.saa.2013.01.09010.1016/j.saa.2013.01.090 ↗
41. 10.1016/j.jhep.2013.07.00110.1016/j.jhep.2013.07.001 ↗
42. 10.1039/C3TB21348J10.1039/C3TB21348J ↗
43. 10.1016/j.matlet.2012.11.04510.1016/j.matlet.2012.11.045 ↗
44. 10.1002/open.20110000310.1002/open.201100003 ↗
45. 10.1158/0008-5472.CAN-08-156510.1158/0008-5472.CAN-08-1565 ↗
46. 10.1023/A:101134222062110.1023/A:1011342220621 ↗
47. 10.1002/mrm.113310.1002/mrm.1133 ↗
48. 10.1016/j.bmcl.2009.06.08610.1016/j.bmcl.2009.06.086 ↗
49. Promoting melanoma growth and metastasis by enhancing VEGF expression
50. 10.1038/ncomms594410.1038/ncomms5944 ↗